skosuri

18 ms·

121.
Tom Knight's Ginkgo Bioworks Seeks to Reinvent Moore's Law Through Biochemistry(forbes.com)
5 points by skosuri 10y ago|0 comments
122.
by skosuri 10y ago
Did they pay the lawyers in coupons for ticketmaster as well?
123.
by skosuri 10y ago
It looks like he also flipped classrooms and was active within the department service-wise. That's a pretty crazy decision not to tenure him from the outside.
124.
by skosuri 10y ago
Cannot agree with this more. I'm a little sick of all these articles on how science is in so much trouble and is doomed. I've been a biologist now for ~18 years. In that time, I've seen so much advancement and real breakthro
125.
by skosuri 10y ago
Tamed mink (1) Untamed mink (2) Note the coat color change happened during selection. Tame cute foxes (3) Bred foxes (not for tameness) (4) Excuse my shoddy camerawork. (1) https://www.dropbox.com/s/9h5imx8kr3zrxe4&#x2F
126.
by skosuri 10y ago
About 4 years ago I gave a talk at a genomics conference in Novosibirsk. I asked to go to this facility and it was super interesting. They were also doing similar experiments on minks and a few other mammals. I was pretty surprised on how f
127.
by skosuri 10y ago
This effort was made possible by the earlier work by Isaacs and Church groups on reclaiming the UAG stop codon by removing all instances of it genome wide [1]. Today the Church group published a followup on progress on removing six more co
128.
by skosuri 10y ago
Agreed. You'd probably enjoy this piece by Sean Eddy: http://journals.plos.org/ploscompbiol/article?id=10.1371%2Fj...
129.
by skosuri 10y ago
1. There are many places this could have been published without an importance review, eg PLoS ONE. 2. I think anyone interested in the replication problem needs to read this piece [1] by Peter Walter. As he put it: "It is much harder t
130.
by skosuri 10y ago
Agreed and second Judson's "The Eighth Day of Creation" [1]. One of the best books that covers the history of the molecular biology revolution, told by a master historian who interviewed the major players extensively. It&#x2
131.
by skosuri 10y ago
IMO & IANAL: IP of one form or another is probably necessary and beneficial for bio. If you make an invention, and it's trivially copied, then you need some protection to commercialize. There are a few options: 1. patents -> the
132.
by skosuri 10y ago
Interesting that this is coming up again. Over a decade ago, we designed and built a synthetic, refactored phage [1]. At the time, we (Drew Endy, Leon Chan, and I) had discussions with lawyers about copyrighting and open-sourcing it. The la
133.
Towards an integration of deep learning and neuroscience(biorxiv.org)
1 points by skosuri 10y ago|0 comments
134.
by skosuri 10y ago
Can you think of a low impact paper that later turned out to be too novel to get published in a high impact journal at the time? How often do you think this happens? I for one don't see this a lot. What I see more often are people t
135.
by skosuri 10y ago
I also think there is a huge bias for publishing "novel" findings... that's how you get into bigger journals.
136.
Genome Project – Write(nytimes.com)
4 points by skosuri 10y ago|0 comments
137.
Interview with George Church on his scientific drive(news.harvard.edu)
2 points by skosuri 10y ago|0 comments
138.
by skosuri 10y ago
I've spent a couple of years out of the game and was fine. It is on the rare side though.
139.
by skosuri 11y ago
Also not part of this study, but an earlier one (ref 6). Basically DNA has been recovered from corpses that are thousands of years old. If stored properly, it is at least extrapolated to last up to millions of years [1]. 1. http:/&#x2
140.
by skosuri 11y ago
Basically no one would dream foolhardy dreams anymore, which would make society horrible.
141.
by skosuri 11y ago
Well the Zhang lab did find another CRISPR based system that sidesteps the Cas9-based patents [1]. [1] http://www.cell.com/abstract/S0092-8674(15)01200-3
142.
by skosuri 11y ago
Ugh. I don't understand all this recent Broad/Lander vitriol. You can ask pretty much anyone in the field and they'll all say the work was a tour de force (see first comment in the article for instance). Focusing on the press
143.
by skosuri 11y ago
I sat next to you and I wasn't surprised.
144.
by skosuri 11y ago
I found this article to be fascinating. It reminds me of a few other rare disease stories, like those of Matt Might's [1, 2]. [1] http://www.newyorker.com/magazine/2014/07/21/one-of-a-kind- [2] ht
145.
by skosuri 11y ago
1. You said, "He doesn't do CRISPR research." If you are going ad hominim, it's usually better if you get your facts right. 2. FWIW, I think you are largely rewriting history by your comment. The dominant feeling I rem
146.
by skosuri 11y ago
Wow, This is a lot of anger. I for one appreciated the viewpoint (taken with an eye that it is his view). Anyways, for what it's worth, Lander's lab has done a bunch with CRISPR's so your initial premise is flat out wrong [eg
147.
by skosuri 11y ago
But reviews at Cell are academic papers; they are peer reviewed. Doudna has direct financial conflicts, it should have been disclosed. The viewpoints are usually solicited and not peer reviewed (at least ones I've been involved with),
148.
by skosuri 11y ago
Possibly both. Either way, tons of people always get left out.
149.
by skosuri 11y ago
According to cell, he did disclose it and they chose not to use it because he didn't have a personal financial stake [1]. As a note, Doudna's review also had no conflict of interest despite her personal stake. 1. https:/&#x2
150.
by skosuri 11y ago
Just looked up the author and found this: http://www.aaaivideos.org/2013/06_task_relevant_roadmaps/ The eyes are so creepy.

More ›